Myriad Business Model Canvas
Full Business Model Canvas: Editable playbook for investors, founders, analysts
Unlock Myriad’s strategic playbook with the full Business Model Canvas. This in-depth, editable guide maps value propositions, revenue streams, partnerships, and scaling levers. Ideal for investors, founders, and analysts seeking actionable insights. Download the complete Canvas in Word and Excel to benchmark and execute faster.
Partnerships
Academic & research institutions
Collaborations with universities and cancer centers accelerate biomarker discovery and clinical validation, supporting Myriad's multi-site studies across 20+ centers by 2024 to strengthen evidence for clinical utility and guideline inclusion. Access to biobanks with over 200,000 biospecimens and diverse cohorts improves test performance and generalizability. Co-authorship and data sharing produced 150+ peer-reviewed publications, enhancing scientific credibility.
Hospitals, health systems, and clinics
Integrated partnerships with hospitals and clinics enable streamlined ordering, coordinated sample collection, and secure result delivery embedded into EHR workflows. Embedding Myriad workflows within oncology and women’s health pathways increases clinician adoption and guideline-concordant testing. Joint quality initiatives reduce turnaround times and improve diagnostic outcomes. Alignment with value-based care and ACO models in 2024 supports shared savings and population health goals.
Pharmaceutical & biotech companies
Co-development with pharmaceutical and biotech partners enables Myriad to deliver companion diagnostics that accelerate targeted therapy development and trial enrollment; the companion diagnostics market exceeded $5 billion in 2024 and FDA had approved over 40 companion diagnostics by 2024. Regulatory-aligned studies directly link test results to drug response and safety, supporting label expansions. Commercial agreements bundle testing with therapy access programs and real-world evidence generation enhances market penetration and reimbursement negotiations.
Payers and provider networks
Contracting with insurers and provider networks secures coverage and streamlines reimbursement and prior authorization workflows, supported by published health economic studies that have influenced favorable payer policies. Population screening pilots in ACOs and IDNs have demonstrated measurable cost-offsets and care pathway efficiencies. Continuous, data-driven outcomes reporting sustains and expands long-term payer relationships.
- Coverage-driven contracting
- Health economics evidence
- ACO/IDN screening pilots
- Outcomes-based payer reporting
Health IT, EHR, and lab logistics vendors
Integrations with EHR/CPOE enable e-ordering and discrete result delivery, supported by ~96% EHR adoption in US hospitals (ONC 2024). Interoperability partners ensure HL7/FHIR compliance and workflow fit. Logistics partners optimize kit distribution and specimen transport. Cybersecurity vendors safeguard PHI and regulatory adherence.
- EHR/CPOE: e-ordering, discrete results
- Interoperability: HL7/FHIR compliance
- Logistics: kit distribution, specimen transport
- Security: PHI protection, regulatory compliance
200k specimens, 96% EHR reach, companion Dx in >$5B market
Partnerships with 20+ academic and clinical centers and access to 200,000+ biospecimens drive biomarker validation and 150+ peer-reviewed papers. Hospital and EHR integrations (96% US adoption 2024) streamline orders and results. Pharma co-development supports companion diagnostics in a >$5B market (2024). Payer contracts and ACO pilots secure coverage and cost-offset evidence.
| Partner | Metric |
|---|---|
| Academia/Clinics | 20+ centers |
| Biobanks | 200,000+ specimens |
| Pubs | 150+ |
| EHR | 96% adoption |
| Companion Dx | >$5B (2024) |
What is included in the product
Detailed Word Document
Myriad Business Model Canvas delivers a comprehensive, pre-written BMC aligned with the company’s strategy, mapping customer segments, channels, value propositions, revenue streams, key activities, resources, partners, cost structure and customer relationships. Ideal for presentations and funding discussions, it includes competitive analysis, SWOT-linked insights and a polished layout to support validation and decision-making.
Customizable Excel Spreadsheet
Condenses company strategy into a digestible one-page canvas with editable cells, saving hours of formatting and enabling teams to quickly identify core components, collaborate, and adapt models for boardrooms, teaching, or fast deliverables.
Activities
Assay development & clinical validation
Design and optimize panels such as the 25-gene myRisk hereditary cancer panel and the 12-gene GeneSight pharmacogenomics panel for oncology, women’s health, and drug response, updating assays as new variants and biomarkers emerge. Conduct rigorous analytical and clinical validation under CLIA/CAP and FDA expectations, supporting submissions and lab accreditation. Publish evidence—over 30 peer-reviewed studies by 2024—to drive guideline inclusion and payer coverage.
High-complexity lab operations
As of 2024 Myriad operates CLIA/CAP-certified laboratories with rigorous QA/QC programs, validated assays and proficiency testing to ensure clinical-grade results. Labs manage sample accessioning, high-throughput sequencing and orthogonal variant confirmation with documented SOPs. Scalable automation supports rapid turnaround while strict chain-of-custody and compliance documentation maintain audit readiness and patient data integrity.
Bioinformatics & variant interpretation
Operating high-throughput pipelines for alignment, variant calling and annotation, Myriad curates internal and public resources (ClinVar >1.8 million submissions in 2024) and applies ACMG/AMP criteria for standardized interpretation; machine learning models boost classification sensitivity and reduce VUS rates, while clinician-friendly, actionable reports summarize pathogenicity, evidence and recommended follow-up for tens of thousands of tests processed annually.
Market access & medical affairs
Market access and medical affairs negotiate payer contracts and streamline prior-authorization pathways, educate clinicians with peer-reviewed evidence, guidelines, and real-world utility data, support KOL engagement and advisory boards, and deliver outcomes and health-economic analyses to demonstrate clinical and budgetary value.
- payer negotiations
- prior authorization workflows
- clinician education
- KOL/advisory boards
- outcomes & HEOR
Regulatory, privacy, and security management
Regulatory, privacy, and security management includes preparing submissions and maintaining audit readiness, supporting 20+ regulatory filings annually. Ensuring HIPAA, GDPR, and data governance compliance is core, with the average data breach cost at 4.45M USD (IBM, 2024). Managing cybersecurity controls and vendor risk while overseeing post-market surveillance and quality systems ensures continuous market access and patient safety.
- Regulatory filings: 20+ per year
- Average breach cost: 4.45M USD (IBM 2024)
- HIPAA/GDPR/data governance enforcement
- Vendor risk + post-market surveillance
CLIA/CAP genomic panels: high-throughput testing, ML interpretation, 30+ studies, robust security
Design and update clinical panels (25-gene myRisk, 12-gene GeneSight) with CLIA/CAP labs, processing tens of thousands of tests annually and publishing 30+ peer-reviewed studies by 2024. Maintain high-throughput sequencing, ML-supported interpretation (ClinVar >1.8M submissions in 2024) and QA/QC for clinical-grade reports. Manage 20+ regulatory filings/year, payer negotiations, prior-authorization workflows, and HIPAA/GDPR-compliant security (avg breach cost 4.45M USD 2024).
| Metric | Value (2024) |
|---|---|
| Tests processed/yr | Tens of thousands |
| Peer-reviewed studies | 30+ |
| Regulatory filings/yr | 20+ |
| ClinVar submissions | >1.8M |
| Avg breach cost | 4.45M USD |
Delivered as Displayed
Business Model Canvas
The document you're previewing is the exact Myriad Business Model Canvas you'll receive after purchase. It’s not a mockup—this live preview shows the final, fully formatted canvas with all content intact. After buying, you’ll instantly download the same editable Word and Excel files, ready to use.
Full Business Model Canvas: Editable playbook for investors, founders, analysts
Unlock Myriad’s strategic playbook with the full Business Model Canvas. This in-depth, editable guide maps value propositions, revenue streams, partnerships, and scaling levers. Ideal for investors, founders, and analysts seeking actionable insights. Download the complete Canvas in Word and Excel to benchmark and execute faster.
Partnerships
Academic & research institutions
Collaborations with universities and cancer centers accelerate biomarker discovery and clinical validation, supporting Myriad's multi-site studies across 20+ centers by 2024 to strengthen evidence for clinical utility and guideline inclusion. Access to biobanks with over 200,000 biospecimens and diverse cohorts improves test performance and generalizability. Co-authorship and data sharing produced 150+ peer-reviewed publications, enhancing scientific credibility.
Hospitals, health systems, and clinics
Integrated partnerships with hospitals and clinics enable streamlined ordering, coordinated sample collection, and secure result delivery embedded into EHR workflows. Embedding Myriad workflows within oncology and women’s health pathways increases clinician adoption and guideline-concordant testing. Joint quality initiatives reduce turnaround times and improve diagnostic outcomes. Alignment with value-based care and ACO models in 2024 supports shared savings and population health goals.
Pharmaceutical & biotech companies
Co-development with pharmaceutical and biotech partners enables Myriad to deliver companion diagnostics that accelerate targeted therapy development and trial enrollment; the companion diagnostics market exceeded $5 billion in 2024 and FDA had approved over 40 companion diagnostics by 2024. Regulatory-aligned studies directly link test results to drug response and safety, supporting label expansions. Commercial agreements bundle testing with therapy access programs and real-world evidence generation enhances market penetration and reimbursement negotiations.
Payers and provider networks
Contracting with insurers and provider networks secures coverage and streamlines reimbursement and prior authorization workflows, supported by published health economic studies that have influenced favorable payer policies. Population screening pilots in ACOs and IDNs have demonstrated measurable cost-offsets and care pathway efficiencies. Continuous, data-driven outcomes reporting sustains and expands long-term payer relationships.
- Coverage-driven contracting
- Health economics evidence
- ACO/IDN screening pilots
- Outcomes-based payer reporting
Health IT, EHR, and lab logistics vendors
Integrations with EHR/CPOE enable e-ordering and discrete result delivery, supported by ~96% EHR adoption in US hospitals (ONC 2024). Interoperability partners ensure HL7/FHIR compliance and workflow fit. Logistics partners optimize kit distribution and specimen transport. Cybersecurity vendors safeguard PHI and regulatory adherence.
- EHR/CPOE: e-ordering, discrete results
- Interoperability: HL7/FHIR compliance
- Logistics: kit distribution, specimen transport
- Security: PHI protection, regulatory compliance
200k specimens, 96% EHR reach, companion Dx in >$5B market
Partnerships with 20+ academic and clinical centers and access to 200,000+ biospecimens drive biomarker validation and 150+ peer-reviewed papers. Hospital and EHR integrations (96% US adoption 2024) streamline orders and results. Pharma co-development supports companion diagnostics in a >$5B market (2024). Payer contracts and ACO pilots secure coverage and cost-offset evidence.
| Partner | Metric |
|---|---|
| Academia/Clinics | 20+ centers |
| Biobanks | 200,000+ specimens |
| Pubs | 150+ |
| EHR | 96% adoption |
| Companion Dx | >$5B (2024) |
What is included in the product
Detailed Word Document
Myriad Business Model Canvas delivers a comprehensive, pre-written BMC aligned with the company’s strategy, mapping customer segments, channels, value propositions, revenue streams, key activities, resources, partners, cost structure and customer relationships. Ideal for presentations and funding discussions, it includes competitive analysis, SWOT-linked insights and a polished layout to support validation and decision-making.
Customizable Excel Spreadsheet
Condenses company strategy into a digestible one-page canvas with editable cells, saving hours of formatting and enabling teams to quickly identify core components, collaborate, and adapt models for boardrooms, teaching, or fast deliverables.
Activities
Assay development & clinical validation
Design and optimize panels such as the 25-gene myRisk hereditary cancer panel and the 12-gene GeneSight pharmacogenomics panel for oncology, women’s health, and drug response, updating assays as new variants and biomarkers emerge. Conduct rigorous analytical and clinical validation under CLIA/CAP and FDA expectations, supporting submissions and lab accreditation. Publish evidence—over 30 peer-reviewed studies by 2024—to drive guideline inclusion and payer coverage.
High-complexity lab operations
As of 2024 Myriad operates CLIA/CAP-certified laboratories with rigorous QA/QC programs, validated assays and proficiency testing to ensure clinical-grade results. Labs manage sample accessioning, high-throughput sequencing and orthogonal variant confirmation with documented SOPs. Scalable automation supports rapid turnaround while strict chain-of-custody and compliance documentation maintain audit readiness and patient data integrity.
Bioinformatics & variant interpretation
Operating high-throughput pipelines for alignment, variant calling and annotation, Myriad curates internal and public resources (ClinVar >1.8 million submissions in 2024) and applies ACMG/AMP criteria for standardized interpretation; machine learning models boost classification sensitivity and reduce VUS rates, while clinician-friendly, actionable reports summarize pathogenicity, evidence and recommended follow-up for tens of thousands of tests processed annually.
Market access & medical affairs
Market access and medical affairs negotiate payer contracts and streamline prior-authorization pathways, educate clinicians with peer-reviewed evidence, guidelines, and real-world utility data, support KOL engagement and advisory boards, and deliver outcomes and health-economic analyses to demonstrate clinical and budgetary value.
- payer negotiations
- prior authorization workflows
- clinician education
- KOL/advisory boards
- outcomes & HEOR
Regulatory, privacy, and security management
Regulatory, privacy, and security management includes preparing submissions and maintaining audit readiness, supporting 20+ regulatory filings annually. Ensuring HIPAA, GDPR, and data governance compliance is core, with the average data breach cost at 4.45M USD (IBM, 2024). Managing cybersecurity controls and vendor risk while overseeing post-market surveillance and quality systems ensures continuous market access and patient safety.
- Regulatory filings: 20+ per year
- Average breach cost: 4.45M USD (IBM 2024)
- HIPAA/GDPR/data governance enforcement
- Vendor risk + post-market surveillance
CLIA/CAP genomic panels: high-throughput testing, ML interpretation, 30+ studies, robust security
Design and update clinical panels (25-gene myRisk, 12-gene GeneSight) with CLIA/CAP labs, processing tens of thousands of tests annually and publishing 30+ peer-reviewed studies by 2024. Maintain high-throughput sequencing, ML-supported interpretation (ClinVar >1.8M submissions in 2024) and QA/QC for clinical-grade reports. Manage 20+ regulatory filings/year, payer negotiations, prior-authorization workflows, and HIPAA/GDPR-compliant security (avg breach cost 4.45M USD 2024).
| Metric | Value (2024) |
|---|---|
| Tests processed/yr | Tens of thousands |
| Peer-reviewed studies | 30+ |
| Regulatory filings/yr | 20+ |
| ClinVar submissions | >1.8M |
| Avg breach cost | 4.45M USD |
Delivered as Displayed
Business Model Canvas
The document you're previewing is the exact Myriad Business Model Canvas you'll receive after purchase. It’s not a mockup—this live preview shows the final, fully formatted canvas with all content intact. After buying, you’ll instantly download the same editable Word and Excel files, ready to use.
Description
Full Business Model Canvas: Editable playbook for investors, founders, analysts
Unlock Myriad’s strategic playbook with the full Business Model Canvas. This in-depth, editable guide maps value propositions, revenue streams, partnerships, and scaling levers. Ideal for investors, founders, and analysts seeking actionable insights. Download the complete Canvas in Word and Excel to benchmark and execute faster.
Partnerships
Academic & research institutions
Collaborations with universities and cancer centers accelerate biomarker discovery and clinical validation, supporting Myriad's multi-site studies across 20+ centers by 2024 to strengthen evidence for clinical utility and guideline inclusion. Access to biobanks with over 200,000 biospecimens and diverse cohorts improves test performance and generalizability. Co-authorship and data sharing produced 150+ peer-reviewed publications, enhancing scientific credibility.
Hospitals, health systems, and clinics
Integrated partnerships with hospitals and clinics enable streamlined ordering, coordinated sample collection, and secure result delivery embedded into EHR workflows. Embedding Myriad workflows within oncology and women’s health pathways increases clinician adoption and guideline-concordant testing. Joint quality initiatives reduce turnaround times and improve diagnostic outcomes. Alignment with value-based care and ACO models in 2024 supports shared savings and population health goals.
Pharmaceutical & biotech companies
Co-development with pharmaceutical and biotech partners enables Myriad to deliver companion diagnostics that accelerate targeted therapy development and trial enrollment; the companion diagnostics market exceeded $5 billion in 2024 and FDA had approved over 40 companion diagnostics by 2024. Regulatory-aligned studies directly link test results to drug response and safety, supporting label expansions. Commercial agreements bundle testing with therapy access programs and real-world evidence generation enhances market penetration and reimbursement negotiations.
Payers and provider networks
Contracting with insurers and provider networks secures coverage and streamlines reimbursement and prior authorization workflows, supported by published health economic studies that have influenced favorable payer policies. Population screening pilots in ACOs and IDNs have demonstrated measurable cost-offsets and care pathway efficiencies. Continuous, data-driven outcomes reporting sustains and expands long-term payer relationships.
- Coverage-driven contracting
- Health economics evidence
- ACO/IDN screening pilots
- Outcomes-based payer reporting
Health IT, EHR, and lab logistics vendors
Integrations with EHR/CPOE enable e-ordering and discrete result delivery, supported by ~96% EHR adoption in US hospitals (ONC 2024). Interoperability partners ensure HL7/FHIR compliance and workflow fit. Logistics partners optimize kit distribution and specimen transport. Cybersecurity vendors safeguard PHI and regulatory adherence.
- EHR/CPOE: e-ordering, discrete results
- Interoperability: HL7/FHIR compliance
- Logistics: kit distribution, specimen transport
- Security: PHI protection, regulatory compliance
200k specimens, 96% EHR reach, companion Dx in >$5B market
Partnerships with 20+ academic and clinical centers and access to 200,000+ biospecimens drive biomarker validation and 150+ peer-reviewed papers. Hospital and EHR integrations (96% US adoption 2024) streamline orders and results. Pharma co-development supports companion diagnostics in a >$5B market (2024). Payer contracts and ACO pilots secure coverage and cost-offset evidence.
| Partner | Metric |
|---|---|
| Academia/Clinics | 20+ centers |
| Biobanks | 200,000+ specimens |
| Pubs | 150+ |
| EHR | 96% adoption |
| Companion Dx | >$5B (2024) |
What is included in the product
Detailed Word Document
Myriad Business Model Canvas delivers a comprehensive, pre-written BMC aligned with the company’s strategy, mapping customer segments, channels, value propositions, revenue streams, key activities, resources, partners, cost structure and customer relationships. Ideal for presentations and funding discussions, it includes competitive analysis, SWOT-linked insights and a polished layout to support validation and decision-making.
Customizable Excel Spreadsheet
Condenses company strategy into a digestible one-page canvas with editable cells, saving hours of formatting and enabling teams to quickly identify core components, collaborate, and adapt models for boardrooms, teaching, or fast deliverables.
Activities
Assay development & clinical validation
Design and optimize panels such as the 25-gene myRisk hereditary cancer panel and the 12-gene GeneSight pharmacogenomics panel for oncology, women’s health, and drug response, updating assays as new variants and biomarkers emerge. Conduct rigorous analytical and clinical validation under CLIA/CAP and FDA expectations, supporting submissions and lab accreditation. Publish evidence—over 30 peer-reviewed studies by 2024—to drive guideline inclusion and payer coverage.
High-complexity lab operations
As of 2024 Myriad operates CLIA/CAP-certified laboratories with rigorous QA/QC programs, validated assays and proficiency testing to ensure clinical-grade results. Labs manage sample accessioning, high-throughput sequencing and orthogonal variant confirmation with documented SOPs. Scalable automation supports rapid turnaround while strict chain-of-custody and compliance documentation maintain audit readiness and patient data integrity.
Bioinformatics & variant interpretation
Operating high-throughput pipelines for alignment, variant calling and annotation, Myriad curates internal and public resources (ClinVar >1.8 million submissions in 2024) and applies ACMG/AMP criteria for standardized interpretation; machine learning models boost classification sensitivity and reduce VUS rates, while clinician-friendly, actionable reports summarize pathogenicity, evidence and recommended follow-up for tens of thousands of tests processed annually.
Market access & medical affairs
Market access and medical affairs negotiate payer contracts and streamline prior-authorization pathways, educate clinicians with peer-reviewed evidence, guidelines, and real-world utility data, support KOL engagement and advisory boards, and deliver outcomes and health-economic analyses to demonstrate clinical and budgetary value.
- payer negotiations
- prior authorization workflows
- clinician education
- KOL/advisory boards
- outcomes & HEOR
Regulatory, privacy, and security management
Regulatory, privacy, and security management includes preparing submissions and maintaining audit readiness, supporting 20+ regulatory filings annually. Ensuring HIPAA, GDPR, and data governance compliance is core, with the average data breach cost at 4.45M USD (IBM, 2024). Managing cybersecurity controls and vendor risk while overseeing post-market surveillance and quality systems ensures continuous market access and patient safety.
- Regulatory filings: 20+ per year
- Average breach cost: 4.45M USD (IBM 2024)
- HIPAA/GDPR/data governance enforcement
- Vendor risk + post-market surveillance
CLIA/CAP genomic panels: high-throughput testing, ML interpretation, 30+ studies, robust security
Design and update clinical panels (25-gene myRisk, 12-gene GeneSight) with CLIA/CAP labs, processing tens of thousands of tests annually and publishing 30+ peer-reviewed studies by 2024. Maintain high-throughput sequencing, ML-supported interpretation (ClinVar >1.8M submissions in 2024) and QA/QC for clinical-grade reports. Manage 20+ regulatory filings/year, payer negotiations, prior-authorization workflows, and HIPAA/GDPR-compliant security (avg breach cost 4.45M USD 2024).
| Metric | Value (2024) |
|---|---|
| Tests processed/yr | Tens of thousands |
| Peer-reviewed studies | 30+ |
| Regulatory filings/yr | 20+ |
| ClinVar submissions | >1.8M |
| Avg breach cost | 4.45M USD |
Delivered as Displayed
Business Model Canvas
The document you're previewing is the exact Myriad Business Model Canvas you'll receive after purchase. It’s not a mockup—this live preview shows the final, fully formatted canvas with all content intact. After buying, you’ll instantly download the same editable Word and Excel files, ready to use.
